In a phase 2 trial, the IL-33 blocker itepekimab reduced exacerbations and improved lung function in a subgroup of COPD patients who were former smokers, irrespective of baseline blood eosinophil status [116]. Here, IL33 is linked to chronic obstructive pulmonary disease.